Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVOBOND
2021-005071-40Phase 3Completed
- Sponsor
- Alvotech
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of DenOsteoRel and denosumab in osteoporosis (2 arms), sponsored by Alvotech. Primary endpoint: Percent change from baseline in lumbar spine bone mineral density at 12 months. Started Apr 2022; status: completed.
02
Drugs
DenOsteoReldenosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2021-005071-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005071-40.